233,851 Shares in Fulcrum Therapeutics, Inc. $FULC Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 233,851 shares of the company’s stock, valued at approximately $856,000. Hennion & Walsh Asset Management Inc. owned approximately 0.35% of Fulcrum Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of FULC. Suvretta Capital Management LLC lifted its position in Fulcrum Therapeutics by 21.9% during the 4th quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company’s stock worth $74,206,000 after buying an additional 1,180,111 shares in the last quarter. Nantahala Capital Management LLC increased its position in shares of Fulcrum Therapeutics by 8.9% in the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after acquiring an additional 382,485 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Fulcrum Therapeutics by 53.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock valued at $31,572,000 after acquiring an additional 1,589,000 shares during the last quarter. Braidwell LP raised its holdings in Fulcrum Therapeutics by 1,294.7% during the fourth quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock worth $34,622,000 after acquiring an additional 2,841,734 shares in the last quarter. Finally, Siren L.L.C. raised its holdings in Fulcrum Therapeutics by 20.5% during the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock worth $18,024,000 after acquiring an additional 400,000 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Insider Activity at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the transaction, the director directly owned 10,927 shares in the company, valued at approximately $39,883.55. This trade represents a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 7.30% of the company’s stock.

Analysts Set New Price Targets

FULC has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th. Citigroup lowered shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research note on Tuesday, June 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 target price on the stock. in a report on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Tuesday, June 2nd. Finally, Leerink Partners cut Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price target for the company. in a report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Stock Down 0.3%

Shares of Fulcrum Therapeutics stock opened at $3.71 on Friday. The stock has a market capitalization of $283.07 million, a price-to-earnings ratio of -3.07 and a beta of 3.05. Fulcrum Therapeutics, Inc. has a twelve month low of $2.83 and a twelve month high of $15.74. The company has a 50-day simple moving average of $3.67 and a two-hundred day simple moving average of $6.48.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, sell-side analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.69 earnings per share for the current fiscal year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.